Literature DB >> 14602705

Congenital idiopathic chylothorax in neonates: chemical pleurodesis with povidone-iodine (Betadine).

O Brissaud1, L Desfrere, R Mohsen, M Fayon, J L Demarquez.   

Abstract

Chylothorax is defined as an accumulation of chyle in the pleural space. This condition usually occurs after an operation, the congenital idiopathic form being rare (1/15<thin>000 births). Recovery is observed within four to six weeks of diagnosis in most cases. Treatment is either conservative or surgical. Four cases are reported of congenital chylothorax (three idiopathic, one accompanied by diffuse lymphangectasia) managed by chemical pleurodesis (intrapleural injection of povidone-iodine). Tolerance was satisfactory: unaltered thyroid function in the three cases explored; one case of transient generalised oedema. Treatment was deemed successful in three of the four cases. One child died from renal failure (unrelated to the chemical pleurodesis). Pleurodesis by povidone-iodine appears to be well tolerated and may represent a good alternative to mechanical abrasion or surgery for congenital idiopathic chylothorax. Its use for refractory chylothorax may also decrease the morbidity related to prolonged hospital stay.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14602705      PMCID: PMC1763240          DOI: 10.1136/fn.88.6.f531

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  15 in total

1.  Congenital chylothorax: what is the best strategy?

Authors:  D Mitanchez; E Walter-Nicolet; R Salomon; F Bavoux; P Hubert
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-03       Impact factor: 5.747

2.  Congenital chylothorax--successful management with chemical pleurodesis.

Authors:  Srinivas Murki; Md Faheemuddin; Pramod Gaddam
Journal:  Indian J Pediatr       Date:  2010-02-08       Impact factor: 1.967

3.  Octreotide in the treatment of neonatal postoperative chylothorax: report of three cases and literature review.

Authors:  João Moreira-Pinto; Paula Rocha; Angélica Osório; Berta Bonet; Fátima Carvalho; Carlos Duarte; Luísa Oliveira
Journal:  Pediatr Surg Int       Date:  2010-09-07       Impact factor: 1.827

4.  Congenital Chylothorax of the Newborn: A Systematic Analysis of Published Cases between 1990 and 2018.

Authors:  Bernhard Resch; Gülsen Sever Yildiz; Friedrich Reiterer
Journal:  Respiration       Date:  2021-09-01       Impact factor: 3.580

Review 5.  Somatostatin or octreotide as treatment options for chylothorax in young children: a systematic review.

Authors:  Charles C Roehr; Andreas Jung; Hans Proquitté; Oliver Blankenstein; Hannes Hammer; Kokila Lakhoo; Roland R Wauer
Journal:  Intensive Care Med       Date:  2006-03-11       Impact factor: 17.440

6.  Postoperative chylothorax development is associated with increased incidence and risk profile for central venous thromboses.

Authors:  M A McCulloch; M R Conaway; J A Haizlip; M L Buck; V E Bovbjerg; T R Hoke
Journal:  Pediatr Cardiol       Date:  2007-11-21       Impact factor: 1.655

7.  Incidence and etiology of chylothorax after congenital heart surgery in children.

Authors:  Parvin Akbari Asbagh; Mohammad Ali Navabi Shirazi; Aliakbar Soleimani; Maryam Razzaz; Naseradine Akbari Asbagh; Hussein Rayatzadeh; Mamak Shariat
Journal:  J Tehran Heart Cent       Date:  2014

8.  An observational study on safety and efficacy of povidone-iodine for pleurodesis in cancer patients.

Authors:  Ayush Makkar; Sanjeev Patni; Anjum Khan Joad; Kamal Kishor Lakhera
Journal:  South Asian J Cancer       Date:  2017 Apr-Jun

9.  Treatment of Chylothorax complicating pulmonary resection with hypertonic glucose Pleurodesis.

Authors:  Kejian Zhang; Changyuan Li; Mingrui Zhang; Yang Li
Journal:  J Cardiothorac Surg       Date:  2021-05-28       Impact factor: 1.637

Review 10.  Congenital pulmonary lymphangiectasia.

Authors:  Carlo Bellini; Francesco Boccardo; Corradino Campisi; Eugenio Bonioli
Journal:  Orphanet J Rare Dis       Date:  2006-10-30       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.